CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
Phase 3 Recruiting
400 enrolled
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
Recruiting
100 enrolled
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Phase 1 Recruiting
30 enrolled
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
Recruiting
20 enrolled
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Phase 2 Recruiting
55 enrolled
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Recruiting
135 enrolled
PRAGMATIC
Phase 2 Recruiting
104 enrolled
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1 Recruiting
86 enrolled
QUATRO-APL
Phase 3 Recruiting
150 enrolled
oncOPAL
Phase NA Recruiting
150 enrolled
Mind-body Medicine for Patients With Malignant Hematological Diseases
Phase NA Recruiting
94 enrolled
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Phase 1 Recruiting
117 enrolled
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Recruiting
80 enrolled
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Phase 1/2 Recruiting
70 enrolled
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
171 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Recruiting
6,000 enrolled
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
99,999 enrolled
UWCCC Molecular Tumor Board Registry
Recruiting
10,000 enrolled
MK-3475-587
Phase 3 Recruiting
3,500 enrolled
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Phase 1 Recruiting
300 enrolled
MonumenTAL-1
Phase 2 Recruiting
510 enrolled 2 FDA
MK-1026-003
Phase 2 Recruiting
490 enrolled
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Phase 1 Recruiting
50 enrolled
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Phase 2 Recruiting
46 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
ADAPT-HEM
Phase 1/2 Recruiting
96 enrolled
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Phase 1/2 Recruiting
320 enrolled
Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
Phase NA Recruiting
200 enrolled
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 Recruiting
1,300 enrolled
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase 1/2 Recruiting
265 enrolled
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recruiting
2,000 enrolled
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 Recruiting
70 enrolled
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Phase 3 Recruiting
218 enrolled
GVHD-PTCy
Phase 2 Recruiting
41 enrolled
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
Recruiting
625 enrolled
IVIG for Infection Prevention After CAR-T-Cell Therapy
Phase 2 Recruiting
150 enrolled
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Recruiting
15,000 enrolled
Longitudinal Studies of Patient With FPDMM
Recruiting
1,000 enrolled
ASAP
Recruiting
25,000 enrolled
PROSPER
Recruiting
100 enrolled
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
Phase NA Recruiting
160 enrolled
(HEM-FLU)
Phase 3 Recruiting
60 enrolled
Organoid
Recruiting
70 enrolled
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Phase 1/2 Recruiting
260 enrolled
NiCE
Phase NA Recruiting
120 enrolled
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Recruiting
38 enrolled
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/2 Recruiting
420 enrolled